Using 6 factors, investigators developed a prognostic index model for the prediction of overall survival in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone after docetaxel.1

The model, which could be used to help make clinical practice decisions as well as assist in patient stratification for clinical trials, was developed by using clinical and laboratory factors from a phase 3 trial of abiraterone in combination with prednisone in patients with mCRPC who had received docetaxel.

Investigators looked at data from 762 patients. A univariate and multivariate Cox model with stepwise procedure were used to identify factors associated with overall survival.

Continue Reading

RELATED: Genotypes Linked With Time to Progression, Overall Survival in Prostate Cancer Treated With ADT

The final model included 6 factors associated with poor prognosis: lactate dehydrogenase > upper limit of normal (ULN; HR, 2.31); Eastern Cooperative Oncology Group performance status of 2 (HR, 2.19); presence of liver metastases (HR, 2.00); albumin ≤ 4 b/dL (HR, 1.54); alkaline phosphatase > ULN (HR, 1.38); and time from start of initial androgen-deprivation therapy to start of treatment ≤ 36 months (HR, 1.30).

Prognostic groups of good, intermediate, and poor were developed using the number of risk factors and relative HRs.


  1. Chi KN, Kheoh T, Ryan CJ, et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel [published online ahead of print December 18, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv594.